fb-pixel Skip to main content

More Life Sciences Headlines

A new coronavirus variant has taken over, sparking concerns of a winter surge

So far, COVID cases don’t seem to be rising, but scientists aren’t sure if that will last. And several studies suggest that new booster shots don’t trigger strong immunity to the new variant.

Boston biotech Jnana raises $107 million and strikes second collaboration with Roche

Jnana also struck its second drug discovery collaboration with the pharma giant Roche that will earn the startup $50 million upfront plus potential milestone payments that could exceed $2 billion.

Head of MassBio trade group is out after serving just over a year

The abrupt leadership changes come at a sensitive time for MassBio, which lobbies for the state’s biotechnolology industry, a pillar of the Massachusetts economy.

Biogen picks Christopher Viehbacher, former leader of Sanofi, as new CEO

Viehbacher, who was formerly chief executive of the pharma giant Sanofi for six years, will lead Biogen starting Monday.

Cambridge tech startup nets $41m to wire up labs

The company’s tech platform helps technicians and scientists monitor key lab metrics like temperature, humidity, light, and vibration from their desktop or mobile device.

Pfizer dominates the COVID drug market. This Watertown biotech wants to change that.

Enanta Pharmaceuticals has started a clinical trial of a pill that it says could be safer than the pharma giant's Paxlovid.

Duke, MIT, and Stanford scientists create RNA technology that could improve genetic therapies

The researchers are already envisioning a bevy of applications in basic research, diagnostics, and therapeutics.

First participant in test of custom gene editing therapy dies

Terry Horgan, 27, was signed up for an experimental treatment aimed at correcting a genetic mutation that caused his muscular dystrophy.